I think that none of the holders, unless they have a background in biotech/medicine, would "know" everything about MIDKINE. If I was in Sweden that day I would certainly want to listen to that disputation. Due diligence in investing doesn't stop at knowing the basics, at least for me, and I believe there are holders who would be interested as well.
Publication: Biomarkers Have Higher Diagnostic and Prognostic Potential Than Other Tools, page-22
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable